SEASONALITY STOCK REPORTS

[mick]

***** EntreMed presents data for phase 2 study of mkc-1 in metastatic breast cancer, results demonstrate durable single agent responses (ENMD) 1.10 : Co announced the presentation of interim results for its Phase 2 clinical study of MKC-1 in patients with metastatic breast cancer. Co said, "MKC-1 is showing good antitumor activity in metastatic breast cancer patients who had failed conventional anthracycline and taxane chemotherapy. In addition, the study has passed a second Data Safety Monitoring Board (DSMB) review without any study modification. This study is an important milestone for our MKC-1 clinical development program as it confirms that MKC-1 does have single-agent activity and is well-tolerated by these advanced breast cancer patients. An additional MKC-1 single-agent study is underway in hematological cancers and a combination study is underway with pemetrexed (Alimta) in non-small cell lung cancer. We plan to evaluate our options for either randomized single- agent or combination studies in breast cancer once this study is complete."